Finlands Akademi  
 
 
 
 
 
Finansieringsbeslut
 
Sökande / Kontakt person Myöhänen, Timo
Organisation Helsingfors universitet
Projektets titel Prolyl oligopeptidase - a potential biomarker and a common drug target for several neurodegenerative diseases?
Beslutnr 318327
Beslutsdatum 03.05.2018
Finansierings period 01.09.2018 - 31.08.2022
Finansiering 450 000
   
Beskrivning av projektet
Dysfunctions on protein Tau has been connected to several neurodegenerative diseases, such as Alzheimer's disease (AD) and other Tauopathies. Similar dysfunctions are seen also in traumatic brain injury (TBI) that doubles the risk for later AD, dementia or other neurodegenerative disease. Current drug-therapies cannot stop or delay the progress of these diseases, and moreover, their impact on symptoms is rather weak. We have not observed that prolyl oligopeptidase (PREP) that has been lately connected to Parkinson's disease, inhibits a phosphatase stabilizing Tau, and PREP inhibitors can increase the activity of the phosphatase. Based on this, the aim of the proposal is to study if PREP inhibitors have an effect on dysfunctions of Tau, and if these compounds could stop or delay the progress of AD and other Tauopathies, or if PREP inhibitors can block harmful events after TBI. Moreover, we aim to characterize if PREP inhibitors could be used as an early biomarker in these disorders.